News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Positive Clinical Data for TASQ - Active Biotech AB’s Novel Treatment of Prostate Cancer
March 9, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN -- (MARKET WIRE) -- March 09, 2007 -- Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Europe
MORE ON THIS TOPIC
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
December 4, 2025
·
2 min read
·
Heather McKenzie
FDA
New Approach Methodologies: Redefining Animal Testing Alternatives
December 4, 2025
·
1 min read
·
BioSpace Insights
Policy
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
December 3, 2025
·
4 min read
·
Jennifer Smith-Parker
Duchenne muscular dystrophy
Capricor Heads Back to FDA With Pivotal Results for DMD Cardiomyopathy Therapy
December 3, 2025
·
3 min read
·
Heather McKenzie
